Service Corporation International (SCI) BofA Securities Leveraged Finance Conference 2025 summary
Event summary combining transcript, slides, and related documents.
BofA Securities Leveraged Finance Conference 2025 summary
3 Feb, 2026Business performance and outlook
Funeral and cemetery segments have normalized post-pandemic, with strong averages and steady growth in contract velocity and value over recent quarters.
Large cemetery sales are lumpy but make up 10%-15% of pre-need sales, with ongoing efforts to grow this segment.
Maintenance capital of $160 million is allocated to cemetery property development, including both community and private family mausoleums.
COVID-19's impact on death rates has normalized, with future volume expected to be flat to slightly down, mirroring pre-pandemic trends.
Earnings growth framework targets 8%-12%, with 5%-7% from base business, assuming flattish funeral volume and mid-single-digit cemetery pre-need growth.
Market share, growth drivers, and technology
Holds 17%-18% revenue market share in deathcare, with 12%-13% in funerals and 27%-28% in cemeteries.
Pre-need growth is driven by a 3,700-3,800 person sales force, CRM analytics, targeted marketing, and ongoing training.
AI is being piloted for obituary writing, lead routing, and analytics, but broader adoption is still in early stages.
Cremation trends and margin dynamics
Cremation mix has slowed to a 50-100 basis point annual increase, now at 57%-58%, with less future pressure expected as urban areas approach 70%-80%.
Each 1% shift in cremation mix impacts EBITDA by about $13 million.
Cemetery margins have grown from 17%-18% to 33% over 15-20 years, driven by pre-need sales and counselor effectiveness.
Funeral margins have risen to 21% due to a new marketing agreement, with further growth expected as Baby Boomer demographics increase volume later this decade.
Latest events from Service Corporation International
- Urban network, pre-need backlog, and tech-driven efficiency fuel growth and future outlook.SCI
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Adjusted EPS rose 8% in Q4 and 9% for the year, with 2026 guidance targeting further growth.SCI
Q4 202513 Feb 2026 - Earnings growth, robust M&A, and tech-driven efficiency position the business for strong future gains.SCI
Raymond James & Associates’ 46th Annual Institutional Investors Conference 20253 Feb 2026 - Q2 revenue up, adjusted EPS down; strong cash flow and capital returns; guidance at lower end.SCI
Q2 20242 Feb 2026 - Q3 2024 delivered stable profits, strong cash flow, and record acquisitions for future growth.SCI
Q3 202417 Jan 2026 - Stabilized volumes, moderated cremation shifts, and strong pre-need sales drive 2026 growth.SCI
UBS Global Healthcare Conference 202513 Jan 2026 - Strong market position, robust cash flow, and strategic growth drive superior shareholder returns.SCI
Investor presentation13 Jan 2026 - Strong market position, robust returns, and growth driven by scale and preneed strategy.SCI
Investor presentation13 Jan 2026 - Industry leader with strong cash flow, superior returns, and 2025 EPS growth aligned with targets.SCI
Investor presentation13 Jan 2026